Elevated 3T proton MRS glutamate levels associated with poor Continuous Performance Test (CPT-0X) scores and genetic risk for schizophrenia

Schizophrenia Research

Volumn 99, Issue 1-3, 2008, Pages 218-224

  Purdon, Scot E ^a   Valiakalayil, Agitha ^a   Hanstock, Christopher C ^a   Seres, Peter ^a   Tibbo, Philip ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Attention; Cognition; CPT; Family study; Glutamate; High risk; Neurochemistry; Neuroimaging

Indexed keywords

GLUTAMIC ACID;

ADULT; ARTICLE; ATTENTION; CLINICAL ARTICLE; COGNITION; CONTROLLED STUDY; FEMALE; GENETIC RISK; HUMAN; MALE; NEUROPSYCHOLOGICAL TEST; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; SCHIZOPHRENIA; SCORING SYSTEM; SIBLING;

ADULT; ATTENTION; COGNITION DISORDERS; CREATINE; DISCRIMINATION (PSYCHOLOGY); FEMALE; FRONTAL LOBE; GENETIC PREDISPOSITION TO DISEASE; GLUTAMIC ACID; HUMANS; INHIBITION (PSYCHOLOGY); MAGNETIC RESONANCE SPECTROSCOPY; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; PATTERN RECOGNITION, VISUAL; PSYCHOMOTOR PERFORMANCE; REACTION TIME; RISK; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SCHIZOTYPAL PERSONALITY DISORDER; SIBLINGS;

EID: 39149114402     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.schres.2007.11.028     Document Type: Article

References (30)

1. Allen P., and Thomson R. On the localized quantification of metabolites with coupled spins. MAGMA 9 (1999) 159-163
2. Callicott J.H., Egan M.F., Bertolino A., Mattay V.S., Langheim F.J.P., Frank J.A., and Weinberger D.R. Hippocampal N-acetyl aspartate in unaffected siblings of patients with schizophrenia: A possible intermediate neurobiological phenotype. Biol. Psychiatry 44 (1998) 941-950
3. Chapman L.J., Chapman J.P., and Raulin M.L. Scales for physical and social anhedonia. J. Abnorm. Psychol. 85 (1975) 374-382
4. Conners C.K. The Conner's Continuous Performance Test (1994), Multi-Health Systems, Toronto
5. Conners C.K., Epstein J.N., Angold A., and Klaric J. Continuous performance test performance in a normative epidemiological sample. J. Abnorm. Child Psychol. 31 5 (2003) 555-562
6. Cornblatt B.A., Risch N.J., Faris G., Friedman D., and Erlenmeyer-Kimling L. The continuous performance test, identical pairs version (CPT-IP): I. New findings about sustained attention in normal families. Psychiatry Res. 26 (1988) 223-238
7. Cosway R., Byrne M., Clafferty R., Hodges A., Grant E., Morris J., Abukmeil S.S., Lawrie S.M., Miller P., Owens D.G., and Johnstone E.C. Sustained attention in young people at high risk for schizophrenia. Psychol. Med. 32 2 (2002) 277-286
8. Delawalla Z., Barch D.M., Fisher Eastep J.L., Thomason E.S., Hanewinkel M.J., Thompson P.A., and Csernansky J.G. Factors mediating cognitive deficits and psychopathology among siblings of individuals with schizophrenia. Schizophr. Bull. 32 (2006) 525-537
9. Eckblad M., and Chapman L.J. Magical ideation as an indicator of schizotypy. J. Consult. Clin. Psychol. 51 (1983) 215-225
10. First M.B., Spitzer R.L., Gibbon M., and Williams J.B.W. Structured Clinical Interview for DSM-IV Axis I Disorders-Clinician Version (1997), American Psychiatric Press Inc., Washington, DC
11. Goff D.C., and Coyle J.T. The emerging role of glutamate in the pathophysiology and treatment of schizophrenia. Am. J. Psychiatry 158 (2001) 1367-1377
12. Gottesman I.I., and Gould T.D. The endophenotype concept in psychiatry: etymology and strategic intentions. Am. J. Psychiatry 160 (2003) 636-645
13. Hollingshead A.B., and Redlich F.C. Social Class and Mental Illness (1958), John Wiley & Sons Inc, New York
14. Kim J.S., Kornhuber H.H., Schmid-Burgk W., and Holmuller B. Low cerebrospinal fluid glutamate in schizophrenic patients and a new hypothesis on schizophrenia. Neurosci. Lett. 20 3 (1980) 379-382
15. Luby E.D., Cohen B.D., Rosenbaum G., Gottlieb J.S., and Kelley R. Study of a new schizophrenomimetic drug;sernyl. AMA Arch. Neurol. Psych. 81 3 (1959) 363-369
16. Ohrmann P., Siegmund A., Suslow T., Pederson A., Spitzberg K., Kersting A., Rothermundt M., Arolt V., Heindel W., and Pfleiderer B. Cognitive impairment and in vivo metabolites in first-episode neuroleptic-naïve and chronic medicated schizophrenic patients: A proton magnetic resonance spectroscopy study. J. Psychiatr. Res. 41 8 (2007) 625-634
17. Ohrmann P., Siegmund A., Suslow T., Spitzberg K., Kersting A., Arolt V., Heindel W., and Pfleiderer B. Evidence for glutamatergic neuronal dysfunction in the prefrontal cortex in chronic but not in first-episode patients with schizophrenia: a proton magnetic resonance spectroscopy study. Schizophr. Res. 73 (2005) 153-157
18. Olney J.W. New mechanisms of excitatory transmitter neurotoxicity. J. Neural Transm. Suppl. 43 (1994) 47-51
19. Provencher S.W. Estimation of metabolite concentrations from localized in vivo proton NMR spectra. Magn. Reson. Med. 30 (1993) 672-679
20. Rosvold H., Mirsky A., Sarason I., Bransome Jr. E.D., and Beck L.H. A continuous performance test of brain damage. J. Consul. Psychol. 20 (1956) 343-350
21. Seidman L.J., Giuliano A.J., Smith C.W., Stone W.S., Glatt S.J., Meyer E., Faraone S.V., Tsuang M.T., and Cornblatt B. Neuropsychological functioning in adolescents and young adults at genetic high risk for schizophrenia and affective psychoses: results from the Harvard and Hillside adolescent high risk studies. Schizophr. Bull. 32 3 (2006) 507-524
22. Snitz B.E., MacDonald A.W., and Carter C.S. Cognitive deficits in unaffected first-degree relatives of schizophrenia patients: a meta-analytic review of putative endophenotypes. Schizophr. Bull. 32 1 (2006) 179-194
23. Tamminga C. Glutamatergic aspects of schizophrenia. Br. J. Psychiatry 174 S37 (1999) 12-15
24. Théberge J., Bartha R., Drost D.J., Menon R.S., Malla A., Takhar J., Neufeld R.W., Rogers J., Pavlosky W., Schaefer B., Densmore M., Al-Semaan Y., and Williamson P.C. Glutamate and glutamine measured with 4.0 T proton MRS in never-treated patients with schizophrenia and healthy volunteers. Am. J. Psychiatry 159 (2002) 1944-1946
25. Théberge J., Al-Semaan Y., Williamson P.C., Menon R.S., Neufeld R.W., Rajakumar N., Schaefer B., Densmore M., and Drost D.J. Glutamate and glutamine in the anterior cingulate and thalamus of medicated patients with chronic schizophrenia and healthy comparison subjects measured with 4.0-T proton MRS. Am. J. Psychiatry 160 (2003) 2231-2233
26. Théberge J., Jensen J.E., and Rowland L.M. Regarding Increased prefrontal and hippocampal glutamate concentration in schizophrenia: Evidence from a magnetic resonance spectroscopy study. Biol. Psychiatry 61 (2007) 1218-1219
27. Tibbo P., Hanstock C., Valiakalayil A., and Allen P. 3-T Proton MRS investigation of glutamate and glutamine in adolescents at high genetic risk for schizophrenia. Am. J. Psychiatry 161 (2004) 1116-1118
28. Van Elst L., Valerius G., Buchert M., Thiel T., Rusch N., Bubl E., Hennig J., Ebert D., and Olbrich H.M. Increased prefrontal and hippocampal glutamate concentration in schizophrenia: evidence from a magnetic resonance spectroscopy study. Biol. Psychiatry 58 (2005) 724-730
29. Van Elst L., Valerius G., Buchert M., Thiel T., Rusch N., Bubl E., Henning J., Ebert D., and Olbrich H.M. Lack of empirical reference data for in vivo magnetic resonance spectroscopic glutamate measurements in humans. Biol. Psychiatry 61 (2007) 1219-1220
30. Wickens T.D. Elementary Signal Detection Theory (2002), Oxford University Press, New York